Proceedings of the National Academy of Sciences · 1991 · 99 citations · 18 references
Life SciencesNeurosciencePharmacologyMolecular NeuroscienceMolecular PharmacologyNeuropharmacologyNeuromodulationNeurotransmissionAdenylate Cyclase RegulationAdenylate Cyclase SignalingAdenylyl Cyclase RegulationG Protein Subunit ActivationLithium Dose-response RelationshipLithium PharmacologyLithium TreatmentSerum Lithium Concentration
A possible role for adenylate cyclase and guanine nucleotide-binding proteins (G proteins) in contributing to the chronic actions of lithium on brain function was investigated in rat cerebral cortex. It was found that chronic treatment of rats with lithium (with therapeutically relevant serum levels of approximately 1 mM) increased levels of mRNA and protein for the calmodulin-sensitive (type 1) and calmodulin-insensitive (type 2) forms of adenylate cyclase and decreased levels of mRNA and protein for the inhibitory G-protein subunits Gi alpha 1 and Gi alpha 2. Chronic lithium did not alter levels of other G-protein subunits, including Go alpha, Gs alpha, and G beta. Lithium regulation of adenylate cyclase and Gi alpha was not seen in response to short-term lithium treatment (with final serum levels of approximately 1 mM) or in response to chronic treatment at a lower dose of lithium (with serum levels of approximately 0.5 mM). The results suggest that up-regulation of adenylate cyclase and down-regulation of Gi alpha could represent part of the molecular mechanism by which lithium alters brain function and exerts its clinical actions in the treatment of affective disorders.
18
Psychopharmacology: The Third Generation of Progress.
Annals of Internal Medicine · 1988 · 2K citations
pl Bl5: A cDNA Clone of the Rat mRNA Encoding Cyclophilin
Patria E. Danielson, Sonja Forss‐Petter, Mary Ann D. Brow et al. · DNA · 1988 · 1K citations
Rose Z. Terwilliger, Dana Beitner‐Johnson, Kevin A. Sevarino et al. · Brain Research · 1991 · 540 citations · Full text